Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a Phase 2 clinical study ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Acalabrutinib (Calquence) yielded high efficacy and a manageable safety profile for the treatment of chronic lymphocytic ...

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...

Combination Therapies. Zanubrutinib Plus Venetoclax. Fixed-duration therapies with Bruton's tyrosine kinase (BTK) inhibitors and BCL2 inhibitors are emerging as a new treatment op ...

Rituxan targets B-cells in CLL by engaging immune cells for antibody-dependent phagocytosis and inducing cell lysis. Autoimmune hemolytic anemia involves the immune system mistakenly destroying red ...

A review of machine learning (ML) models developed to support the management of chronic lymphocytic leukemia (CLL) have demonstrated positive outcomes, including accurate diagnosis and improved work ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 Sixty-nine ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...